Evaluation Pembrolizumab (Keytruda): CADTH Reimbursement Suggestion: Indication: Together with chemotherapy, to the cure of adult patients with locally recurrent unresectable or metastatic triple-adverse breast cancer who've not gained prior chemotherapy for metastatic illness and whose tumours Convey programmed mobile Loss of life-ligand one (merged optimistic rating ≥ ten) as based https://juvenalt276zwt5.plpwiki.com/user